What Is in a Name Change? Moving From the Term PCOS to PMOS

Why It Matters

A scientifically accurate, stigma‑free name will streamline diagnosis, align treatment across specialties, and improve outcomes for millions of women worldwide.

Key Takeaways

• Global consensus renamed PCOS to PMOS, reflecting endocrine and metabolic aspects.
• Patient-led process involved 56 societies, 8,000 professionals, and 90% support.
• New name eliminates misleading “cyst” term, reducing diagnostic confusion.
• Implementation plan includes education, marketing, and impact assessment worldwide.
• Revised terminology aims to improve care coordination beyond gynecologic focus.

Summary

The Lancet Pulse episode discusses the landmark decision to rename polycystic ovarian syndrome (PCOS) as polyendocrine metabolic ovarian syndrome (PMOS). The change reflects a growing scientific consensus that the condition is fundamentally an endocrine and metabolic disorder, not a cystic ovarian disease.

Researchers highlighted that roughly 170 million women worldwide live with the condition, often facing delayed diagnosis and fragmented care focused narrowly on gynecology. A decade‑long, patient‑centered effort involving 56 professional societies, 8,000 health professionals, and extensive surveys achieved a 98 % consensus on the new terminology. Ultrasound data from 2,000 women confirmed the absence of pathological cysts, underscoring the misnomer.

Helena Ted and Terry Bilton emphasized that patients repeatedly expressed anxiety over “cysts,” and the new name directly addresses that stigma. The naming process employed modified Delphi techniques, nominal group methods, and marketing expertise, with patients voting three‑to‑one in favor of the final label.

The rebranding is expected to reshape clinical pathways, research funding, and public awareness, fostering integrated metabolic‑reproductive care and reducing stigma. Implementation strategies now focus on education, global outreach, and impact monitoring to ensure the terminology shift translates into measurable health improvements.

Original Description

In this episode of The Lancet Pulse, Chloe Wilson joins Helena Teede and Terhi Piltonen to discuss a recent health policy published in The Lancet that details a global consensus process that puts forward a new name for PCOS - termed PMOS (polyendocrine metabolic ovarian syndrome) to more accurately reflect the disease process.

Listen now to hear more about the process and how it is hoped the name change will lead to better care for those affected by the condition.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext?dgcid=podcast_acq-may2026_lancetpulse)

The Lancet Pulse is part of the Lancet Group podcast offering. 

Editorial team: Chloe Wilson, Ben Abbott, Matthew Gilbert, and Jonathan Pimm

Podcast editing and production: Matteo Simonetti

Visit https://www.thelancet.com/multimedia (https://www.thelancet.com/multimedia?dgcid=buzzsprout_podcast_tlp_mm)  to learn more about our multimedia offering. 

Find the best science for better lives at https://www.thelancet.com

Follow us today at...

https://thelancet.bsky.social/

https://instagram.com/thelancetgroup

https://facebook.com/thelancetmedicaljournal

https://linkedIn.com/company/the-lancet (https://linkedin.com/company/the-lancet)

https://youtube.com/thelancettv (https://www.youtube.com/thelancettv)